Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of TY-0201R transdermal patch vs oral bisoprolol in Chinese patients with essential hypertension
ChiCTR2400091354Phase 3Completed
- Sponsor
- Peking University People's Hospital
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bisoprolol in essential hypertension (3 arms), sponsored by Peking University People's Hospital. Primary endpoint: Change in seated diastolic blood pressure from baseline after 8 weeks of treatment. Started Jul 2022; status: completed.
02
Drugs
bisoprolol
03
Conditions
essential hypertension
Beyond the preview
Go deeper on ChiCTR2400091354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091354.